Insider Transactions in Q3 2022 at Processa Pharmaceuticals, Inc. (PCSA)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 16
2022
|
David Young Pres. Research & Development |
SELL
Bona fide gift
|
Direct |
9,250
-2.39%
|
-
|
|
Aug 16
2022
|
Robert Michael Floyd Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
7,000
-9.87%
|
-
|
|
Aug 05
2022
|
James H Stanker Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,462
-4.76%
|
$7,386
$3.17 P/Share
|
|
Aug 05
2022
|
James H Stanker Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,601
+12.82%
|
-
|
|
Aug 05
2022
|
David Young Pres. Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,531
-0.65%
|
$7,593
$3.17 P/Share
|
|
Aug 05
2022
|
David Young Pres. Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
7,601
+1.91%
|
-
|
|
Aug 05
2022
|
Virgil Thompson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,169
+6.54%
|
-
|
|
Aug 05
2022
|
Geraldine Pannu |
BUY
Exercise of conversion of derivative security
|
Direct |
1,169
+9.4%
|
-
|
|
Aug 05
2022
|
Patrick Lin Chief Business - Strategy Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,656
-0.6%
|
$7,968
$3.17 P/Share
|
|
Aug 05
2022
|
Patrick Lin Chief Business - Strategy Off |
BUY
Exercise of conversion of derivative security
|
Direct |
7,601
+1.69%
|
-
|
|
Aug 05
2022
|
Wendy Guy Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,601
+3.86%
|
-
|
|
Aug 05
2022
|
Sian Bigora Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,601
+1.85%
|
-
|